{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:46:28Z","timestamp":1792439188655,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"DOI":"10.1007\/s11523-026-01260-x","type":"journal-article","created":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T07:32:20Z","timestamp":1792308740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant Systemic Therapies After Nephrectomy for Renal Cell Carcinoma: A Bayesian Network Meta-Analysis and Multi-Criteria Benefit\u2013Risk Assessment"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2300-8446","authenticated-orcid":false,"given":"Shugo","family":"Yajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Kijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,18]]},"reference":[{"key":"1260_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683\u201394. https:\/\/doi.org\/10.1056\/NEJMoa2106391.","journal-title":"N Engl J Med"},{"key":"1260_CR2","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","volume":"390","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med. 2024;390:1359\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2312695.","journal-title":"N Engl J Med"},{"key":"1260_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.eururo.2025.01.014","volume":"87","author":"J Bedke","year":"2025","unstructured":"Bedke J, Abu Ghanem Y, Albiges L, Bonn S, Campi R, Capitanio U, et al. Updated European Association of Urology guidelines on the use of adjuvant immune checkpoint inhibitors and subsequent therapy for renal cell carcinoma. Eur Urol. 2025;87:491\u20136. https:\/\/doi.org\/10.1016\/j.eururo.2025.01.014.","journal-title":"Eur Urol"},{"key":"1260_CR4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","volume":"400","author":"SK Pal","year":"2022","unstructured":"Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2022;400:1103\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(22)01658-0.","journal-title":"Lancet"},{"key":"1260_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","volume":"401","author":"RJ Motzer","year":"2023","unstructured":"Motzer RJ, Russo P, Gr\u00fcnwald V, Tomita Y, Zurawski B, Parikh O, et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet. 2023;401:821\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(22)02574-0.","journal-title":"Lancet"},{"key":"1260_CR6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1200\/JCO.24.00773","volume":"43","author":"RJ Motzer","year":"2025","unstructured":"Motzer RJ, Bex A, Russo P, Tomita Y, Cutuli HJ, Rojas C, et al. Adjuvant nivolumab for localized renal cell carcinoma at high risk of recurrence after nephrectomy: part B of the randomized, placebo-controlled, phase III CheckMate 914 trial. J Clin Oncol. 2025;43:189\u2013200. https:\/\/doi.org\/10.1200\/JCO.24.00773.","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"1260_CR7","doi-asserted-by":"publisher","first-page":"S1635","DOI":"10.1016\/j.annonc.2025.09.110","volume":"36","author":"J Larkin","year":"2025","unstructured":"Larkin J, Powles TB, Frangou E, Stewart GD, Albiges L, Davis ID, et al. LBA93 First results from RAMPART: an international phase III randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL. Ann Oncol. 2025;36(Suppl. 2):S1635. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.110.","journal-title":"Ann Oncol"},{"issue":"Suppl. 17","key":"1260_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA4511","volume":"44","author":"JMG Larkin","year":"2026","unstructured":"Larkin JMG, Powles T, Frangou E, Stewart GD, Albiges L, Davis ID, et al. Durvalumab monotherapy versus active monitoring for resected primary renal cell carcinoma in RAMPART: an international, phase 3, randomized controlled trial. J Clin Oncol. 2026;44(Suppl. 17):LBA4511. https:\/\/doi.org\/10.1200\/JCO.2026.44.17_suppl.LBA4511.","journal-title":"J Clin Oncol"},{"key":"1260_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa2518245","volume":"395","author":"TK Choueiri","year":"2026","unstructured":"Choueiri TK, Motzer RJ, Karam JA, Yip W, Su\u00e1rez C, Ye D, et al. Adjuvant pembrolizumab plus belzutifan for renal-cell carcinoma. N Engl J Med. 2026;395:32\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2518245.","journal-title":"N Engl J Med"},{"key":"1260_CR10","unstructured":"US Food and Drug Administration. FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma. 2026. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belzutifan-pembrolizumab-adjuvant-treatment-renal-cell-carcinoma. [Accessed 22 Jul 2026]."},{"key":"1260_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103706","volume":"175","author":"IB Riaz","year":"2022","unstructured":"Riaz IB, Sipra QUAR, Naqvi SAA, He H, Siddiqi R, Islam M, et al. Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: a living interactive systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2022;175:103706. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103706.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1260_CR12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33:607\u201317. https:\/\/doi.org\/10.1177\/0272989X12458724.","journal-title":"Med Decis Making"},{"key":"1260_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jval.2015.12.016","volume":"19","author":"K Marsh","year":"2016","unstructured":"Marsh K, IJzerman M, Thokala P, Baltussen R, Boysen M, Kal\u00f3 Z, et al. Multiple criteria decision analysis for health care decision making: emerging good practices: report 2 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19:125\u201337. https:\/\/doi.org\/10.1016\/j.jval.2015.12.016.","journal-title":"Value Health"},{"key":"1260_CR14","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/sim.4194","volume":"30","author":"T Tervonen","year":"2011","unstructured":"Tervonen T, van Valkenhoef G, Buskens E, Hillege HL, Postmus D. A stochastic multicriteria model for evidence-based decision making in drug benefit\u2013risk analysis. Stat Med. 2011;30:1419\u201328. https:\/\/doi.org\/10.1002\/sim.4194.","journal-title":"Stat Med"},{"key":"1260_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11701-025-03124-4","volume":"20","author":"S Yajima","year":"2026","unstructured":"Yajima S, Yoshida S, Chen W, Sato H, Hirakawa A, Fujiwara M, et al. Probabilistic multi-criteria decision analysis comparing robot-assisted and laparoscopic radical nephroureterectomy. J Robot Surg. 2026;20:162. https:\/\/doi.org\/10.1007\/s11701-025-03124-4.","journal-title":"J Robot Surg"},{"key":"1260_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1260_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384. https:\/\/doi.org\/10.7326\/M14-2385.","journal-title":"Ann Intern Med"},{"key":"1260_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1260_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","volume":"93","author":"R Brignardello-Petersen","year":"2018","unstructured":"Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa TA, Rochwerg B, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018;93:36\u201344. https:\/\/doi.org\/10.1016\/j.jclinepi.2017.10.005.","journal-title":"J Clin Epidemiol"},{"key":"1260_CR20","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S1470-2045(24)00211-0","volume":"25","author":"ME Allaf","year":"2024","unstructured":"Allaf ME, Kim SE, Master V, McDermott DF, Harshman LC, Cole SM, et al. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. Lancet Oncol. 2024;25:1038\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(24)00211-0.","journal-title":"Lancet Oncol"},{"key":"1260_CR21","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","volume":"23","author":"T Powles","year":"2022","unstructured":"Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:1133\u201344. https:\/\/doi.org\/10.1016\/S1470-2045(22)00487-9.","journal-title":"Lancet Oncol"},{"issue":"Suppl. 16","key":"1260_CR22","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1200\/JCO.2025.43.16_suppl.4514","volume":"43","author":"NB Haas","year":"2025","unstructured":"Haas NB, Powles T, Tomczak P, Park SH, Venugopal B, Symeonides SN, et al. Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2025;43(Suppl. 16):4514. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4514.","journal-title":"J Clin Oncol"},{"key":"1260_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/14796694.2025.2463276","volume":"21","author":"SR Calhoun","year":"2025","unstructured":"Calhoun SR, Vass C, Myers K, Imai K, Bussberg C, Bhattacharya R, et al. Patient preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment. Future Oncol. 2025;21:843\u201351. https:\/\/doi.org\/10.1080\/14796694.2025.2463276.","journal-title":"Future Oncol"},{"key":"1260_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/oncolo\/oyad231","volume":"29","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Tomczak P, Park SH, Venugopal B, Symeonides S, Hajek J, et al. Patient-reported outcomes in KEYNOTE-564: adjuvant pembrolizumab versus placebo for renal cell carcinoma. Oncologist. 2024;29:142\u201350. https:\/\/doi.org\/10.1093\/oncolo\/oyad231.","journal-title":"Oncologist"},{"issue":"Suppl. 7","key":"1260_CR25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1200\/JCO.2026.44.7_suppl.420","volume":"44","author":"S Merrick","year":"2026","unstructured":"Merrick S, Murphy L, Frangou E, Rush H, Plant H, Nankivell MG, et al. Patient-reported outcomes in resected renal cell carcinoma: active monitoring versus durvalumab and tremelimumab in the RAMPART trial. J Clin Oncol. 2026;44(Suppl. 7):420. https:\/\/doi.org\/10.1200\/JCO.2026.44.7_suppl.420.","journal-title":"J Clin Oncol"},{"key":"1260_CR26","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.annonc.2025.08.007","volume":"36","author":"BI Rini","year":"2025","unstructured":"Rini BI, Albiges L, Tang X, Koeppen H, Bex A, Su\u00e1rez C, et al. Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma. Ann Oncol. 2025;36:1525\u201334. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.007.","journal-title":"Ann Oncol"},{"key":"1260_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.urolonc.2026.05.019","volume":"44","author":"S Yajima","year":"2026","unstructured":"Yajima S, Yoshida S, Chen W, Fukushima H, Tanaka H, Sato H, et al. Mixture cure model analysis of event-free survival in the NIAGARA trial: quantifying the cure fraction benefit of perioperative durvalumab in muscle-invasive bladder cancer. Urol Oncol. 2026;44:120\u20136. https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.019.","journal-title":"Urol Oncol"},{"key":"1260_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2026.102566","volume":"24","author":"M Fujiwara","year":"2026","unstructured":"Fujiwara M, Yoshida S, Yajima S, Tanabe K, Chen W, Sato H, et al. Delayed progression-free survival benefit of belzutifan versus everolimus in LITESPARK-005: a reconstructed time-to-event reanalysis. Clin Genitourin Cancer. 2026;24:102566. https:\/\/doi.org\/10.1016\/j.clgc.2026.102566.","journal-title":"Clin Genitourin Cancer"},{"key":"1260_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.euros.2026.01.013","volume":"85","author":"S Yajima","year":"2026","unstructured":"Yajima S, Chen W, Hirose K, Hirakawa A, Tanabe K, Fujiwara M, et al. Re-evaluating treatments for advanced urothelial carcinoma using restricted mean survival time: a systematic review and network meta-analysis. Eur Urol Open Sci. 2026;85:60\u201370. https:\/\/doi.org\/10.1016\/j.euros.2026.01.013.","journal-title":"Eur Urol Open Sci"},{"key":"1260_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-025-02043-8","volume":"26","author":"E Chiong","year":"2026","unstructured":"Chiong E, Spain L, Patel MI, Ong TA, Wang SS, Tsai YC, et al. Treatment preferences of patients and physicians for early-stage and adjuvant treatment of urothelial carcinoma and renal cell carcinoma in Asia-Pacific: a discrete choice experiment. BMC Urol. 2026;26:149. https:\/\/doi.org\/10.1186\/s12894-025-02043-8.","journal-title":"BMC Urol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01260-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01260-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01260-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:03:06Z","timestamp":1792436586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01260-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,18]]},"references-count":30,"alternative-id":["1260"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01260-x","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,18]]},"assertion":[{"value":"28 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shugo Yajima, Gaku Okumura, Soichiro Yoshida, Hiroshi Fukushima, Hiroyuki Sato, Akihiro Hirakawa, Toshiki Kijima, Hitoshi Masuda, and Yasuhisa Fujii have no conflicts of interest that might be directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a synthesis of aggregate data from previously published reports and did not involve new research on human participants; ethics approval was therefore not required.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The consolidated dataset of published trial-level estimates and event counts, together with the R analysis code, is available from the corresponding author on reasonable request; they are not deposited in a public repository. The final search export and screening log are available from the authors on request.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SY: conceptualization, methodology, formal analysis, data curation, writing (original draft). GO: investigation, data curation, writing (review and editing). SY: investigation, writing (review and editing). HF: investigation, writing (review and editing). HS: critical review of the manuscript. AH: critical review of the manuscript. TK: writing (review and editing). HM: supervision, writing (review and editing). YF: supervision, writing (review and editing). All authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Claude (Anthropic) was used to assist with drafting and language editing of the manuscript and with preparation of the analysis and figure code. The authors reviewed and verified all outputs and take full responsibility for the content of this article.","order":8,"name":"Ethics","label":"Use of Artificial Intelligence Tools","group":{"name":"EthicsHeading","label":"Declarations"}}]}}